Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Ascendis Pharma A\/S

NASDAQ ASND
$205.91 7.78 3.93%
Today share price
Denmark
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 20 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
9.35B
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
9.68B
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
0.65
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
60.02M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
49.57 %

Upcoming events Ascendis Pharma A\/S

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Ascendis Pharma A\/S

Stock analysis Ascendis Pharma A\/S

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-27.38 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
-75.40 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-88.67 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
-3.02 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
180.01 -50.00

Price change Ascendis Pharma A\/S per year

112.93$ 205.91$
Min Max

Summary analysis Ascendis Pharma A\/S

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Ascendis Pharma A\/S

Revenue and net income Ascendis Pharma A\/S

All parameters

About company Ascendis Pharma A\/S

Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Address:
Tuborg Boulevard 12, Hellerup, Denmark, 2900
Company name: Ascendis Pharma A\/S
Issuer ticker: ASND
ISIN: US04351P1012
Country: Denmark
Exchange: NASDAQ
Currency: $
IPO date: 2015-01-28
Sector: Healthcare
Industry: Biotechnology
Site: https://www.ascendispharma.com